We are monitoring the impact of COVID-19 on HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1980
Share on
Share on

Global HIV Therapeutics Market Size, Share, Trends, Growth, COVID19 Impact Analysis Report – Segmented By Drug Class, Application and Region – Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1980
Pages: 175

Global HIV Therapeutics Market Size (2020 to 2025)

The size of the global HIV therapeutics market was worth USD 13.57 billion in 2020. This value is estimated to be growing at a CAGR of 1.4% and worth USD 14.55 billion by 2025.

The human immunodeficiency virus (HIV) infection refers to a kind of retrovirus that causes AIDS. HIV affects some immune cells, and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.

HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. Additionally, HIV can spread from infected mother to child during pregnancy. Some of the symptoms of HIV disease are a slight fever, weakness, swollen glands, cerebral pains, and muscle hurts. Integrase inhibitors section is expected to be the rapidly growing class of antiretroviral medications due to the normal dispatch of extra integrase inhibitors by significant players, such as Gilead Sciences, In. and Merck and Co, Inc.

MARKET DRIVERS:

The growing prevalence of HIV/AIDS leads to increasing HIV therapies, driving growth for the target market.

The availability of efficient therapies is one of the major factors boosting the development of the global HIV therapeutics market. The increasing number of initiatives to control the spread of the HIV epidemic is also propelling the market's growth. Other factors that boost the development of the global HIV therapeutics market are increasing awareness among people, approval of drugs, a robust pipeline of medicines for HIV treatment, and rising healthcare expenditure.

Advancements in diagnostic testing for HIV and the emergence of various testing techniques such as rapid POC testing, ELSIA, viral load testing create lucrative opportunities for the key stakeholders in the market. The HIV therapeutics market is likely to expand further over the forecast period. Increasing preference among people to use self-testing kits and HIV testing kits provide many growth opportunities for the key players in the market. Increasing the adoption of mobile diagnostics tools to detect HIV in developing countries offers growth opportunities for growth in the global HIV therapeutics market.

MARKET RESTRAINTS:

The social stigma associated with HIV infection is the major challenge for critical players in the market, obstructing the growth of the global HIV therapeutics market. Another major factor that is restraining the market's development is the high costs associated with antiretroviral therapies. Increasing resistance to drugs among patients is expected to be limiting the growth of the global HIV therapeutics market during the forecast period. 

Impact of COVID-19 on the global HIV therapeutics market:

The COVID-19 pandemic has harmed the HIV drug market. Furthermore, according to industry experts, the COVID-19 outbreak will have long-term consequences in the coming years. In several nations, the epidemic has resulted in a financial crisis. The human immunodeficiency virus (HIV) is a chronic and life-threatening infection that can be transferred from one person to another through blood or sexual contact. It's a virus that targets CD-4 cells in the immune system, rendering the body resistant to infections and other diseases. Manufacturers' inability to supply ARVs (antiretroviral drugs) on time, the closure of land and air transportation systems, and reduced access to health services within countries resulting from the pandemic are likely to have a detrimental effect on the HIV drugs market in the future.

Furthermore, rescheduling HIV care procedures may result in a potential patient backlog. Until further notice, treatment and lifestyle adjustments may be prescribed in these cases. Moreover, private hospitals and clinics that treat HIV exist in countries such as the United States. Clinics and patients, on the other hand, are encouraged to uphold social distancing norms. As a result, all these factors are expected to affect the HIV drug market in the future.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences

 

This research report on the global HIV therapeutics market has been segmented and sub-segmented based on type, application, and region.

HIV Therapeutics Market - By Type:

  • Nucleoside/Tide Reverse Transcriptase Inhibitors
  • Nucleoside/Tide Analogues
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • CCR5 Inhibitors
  • Fusion Inhibitors

Due to the addition of integrase inhibitors by key players such as Merck & Co. and Gilead Sciences, the product category for integrase inhibitors will expand the fastest. Viral genomic DNA is inserted into the host chromosome by these enzymes during replication. ALLINIs (quinoline-based allosteric IN inhibitors) are quinoline-based allosteric IN inhibitors that potently disrupt HIV-1 replication and are currently in clinical trials.

HIV Therapeutics Market - By Application:

  • HIV Type-1
  • HIV Type-2

HIV-1 is found in the majority of HIV patients. Both HIV forms weaken the immune system, but HIV-2 develops more slowly and is more difficult to spread than HIV-1. The government's and various NGOs' concerted efforts to provide at-risk individuals with greater access to disease testing and treatment for infected persons are a critical factor driving the HIV-1 market development. Furthermore, the advent of generic medicines, which are less costly and chemically similar to branded drugs, adds to HIV medications.

HIV Therapeutics Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America, trailed by Europe, accounted for the highest market share for the HIV therapeutics market in 2019 due to the affordability and availability of costly treatment for HIV infections and developments in medication treatments in this region. Because of the high incidence and prevalence of HIV/AIDS, increasing awareness about infection, surging government initiatives, and blood donations, the North American human immunodeficiency virus therapeutics market dominated the industry in 2016. In the United States, the human immunodeficiency virus (HIV) therapeutics industry is the world's leading national funding source for the HIV epidemic.

Asia is expected to show a high development rate in the HIV therapeutics market in the next couple of years because of an increasing number of HIV-affected people and expanding research exercises for creating HIV medications and immunizations in the region. Due to the new advances in drugs, the Asia Pacific human immunodeficiency virus therapeutics market will expand profitably. Due to their unique patent laws that lead to the patent protection of essential lifesaving drugs, Asian manufacturers prove to be a tough competitor. Furthermore, the prices are doomed to prevent certain manufacturers from entering the market, thus potentially proliferating the industry in terms of volume.

KEY MARKET PLAYERS:

Some of the noteworthy market participants leading the global HIV therapeutics market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche, and Gilead Sciences.

KEY HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • PRODUCT LAUNCH: In July 2019, Merck Company launched a new drug for HIV patients called MK-8591, which has changed its dynamics in the HIV therapeutics market. The company has also developed other medications for the treatment of HIV-1, such as PIFELTRO, and DELSTRIGO, which were released into the market after the completion of their approval by the U.S FDA in June 2018.
  • PRODUCT APPROVAL: In April 2019, ViiV Healthcare developed a drug called Dovato, which the FDA has approved. The patients use the drug for the treatment of HIV-1 infection with a no-treatment history of ARV.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Introduction           

                                5.1.2 integrase inhibitor               

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor         

                                5.1.4  non-nucleoside turn around transcriptase inhibitor             

                                5.1.5 HIV-1 protease inhibitor    

                                5.1.6 pharmacokinetic enhancer              

                                5.1.7 passage inhibitor  

                                5.1.8  Y-o-Y Growth Analysis, Drug class                

                                5.1.9  Market Attractiveness Analysis, Drug class              

                                5.1.10  Market Share Analysis, Drug class              

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 HIV Type-1              

                                5.2.3 HIV Type-2              

                                5.2.4 Y-o-Y Growth Analysis, Application               

                                5.2.5 Market Attractiveness Analysis, Application             

                                5.2.6 Market Share Analysis, Application              

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 Drug Class

                                                6.1.3.3 HIV TYPE 1&2

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 Drug Class

                                                6.1.4.3 HIV TYPE 1&2

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 Drug Class

                                                6.1.5.3 HIV TYPE 1&2

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Athersys                      

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 StemCells                    

                8.3 Cryo Cell International                           

                8.4 Geron Corporation                  

                8.5 Mesoblast                   

                8.6 Aastrom Biosciences                              

                8.7 Celgene Corporation                              

                8.8 Invitrogen                   

                8.9 Cytori Therapeutics                 

                8.10 Retractable Technologies                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Global HIV Therapeutics Market, By Region, From 2020 to 2025 (USD Million)
  2. Global HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  3. Global Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  4. Global Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  5. Global Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  6. Global Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  7. Global Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  8. Global HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  9. Global HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  10. Global HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  11. North America HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  12. North America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  13. North America Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  14. North America Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  15. North America Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  16. North America Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  17. North America HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  18. North America HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  19. North America HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  20. United States HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  21. United States HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  22. Canada HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  23. Canada HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  24. Europe HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  25. Europe Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  26. Europe Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  27. Europe Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  28. Europe Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  29. Europe Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  30. Europe HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  31. Europe HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  32. Europe HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  33. U.K. HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  34. U.K. HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  35. Germany HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  36. Germany HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  37. France HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  38. France HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  39. Italy HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  40. Italy HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  41. Spain HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  42. Spain HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  43. Asia-Pacific HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  44. Asia-Pacific Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  45. Asia-Pacific Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  46. Asia-Pacific Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  47. Asia-Pacific Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  48. Asia-Pacific Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  49. Asia-Pacific HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  50. Asia-Pacific HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  51. Asia-Pacific HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  52. Japan HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  53. Japan HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  54. China HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  55. China HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  56. India HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  57. India HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  58. Australia HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  59. Australia HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  60. South Korea HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  61. South Korea HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  62. Latin America HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  63. Latin America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  64. Latin America Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  65. Latin America Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  66. Latin America Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  67. Latin America Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  68. Latin America HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  69. Latin America HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  70. Latin America HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  71. Brazil HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  72. Brazil HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  73. Argentina HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  74. Argentina HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  75. Mexico HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  76. Mexico HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  77. Rest of Latin America HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  78. Rest of Latin America HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  79. Middle East & Africa HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  80. Middle East & Africa Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2020 to 2025 (USD Million)
  81. Middle East & Africa Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  82. Middle East & Africa Protease inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  83. Middle East & Africa Integrate [strand transfer] inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  84. Middle East & Africa Fusion inhibitors Market, By Region, From 2020 to 2025 (USD Million)
  85. Middle East & Africa HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  86. Middle East & Africa HIV Type 1 Market, By Region, From 2020 to 2025 (USD Million)
  87. Middle East & Africa HIV Type 2 Market, By Region, From 2020 to 2025 (USD Million)
  88. Middle East HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  89. Middle East HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)
  90. Africa HIV Therapeutics Market, By Type, From 2020 to 2025 (USD Million)
  91. Africa HIV Therapeutics Market, By Application, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample